نتایج جستجو برای: cladribine

تعداد نتایج: 689  

Journal: :Military Medical and Pharmaceutical Journal of Serbia 2011

Journal: :Journal of Neurology, Neurosurgery & Psychiatry 2014

2013
Jan Thöne Gisa Ellrichmann

Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system characterized by early inflammatory demyelination and subsequent neurodegeneration. Major therapeutic progress has occurred during the past decade, in particular since the introduction of immunomodulatory agents, however, MS is still an incurable disease. In addition, parenteral application of the currently...

Journal: :The hematology journal : the official journal of the European Haematology Association 2004
Thomas Fietz Kathrin Rieger Alexander Schmittel Eckhard Thiel Wolfgang Knauf

Monoclonal antibodies (mAbs) are gaining increasing importance in the course of nucleoside analogue refractory hairy cell leukaemia (HCL). On the one hand, there is the chimaeric anti-CD20 antibody rituximab, which has been in use in relapsed and refractory HCL for almost 5 years now with moderate activity. Very recently, two major studies examined and reviewed the use of this antibody – howeve...

2015
Tomoyuki Sakai Yasufumi Masaki Nozomi Otsuki Ippei Sakamaki Shinji Kishi Takayoshi Miyazono Yoshimasa Urasaki Jun Murakami Tomomi Satoh Takuji Nakamura Haruka Iwao Akio Nakajima Takafumi Kawanami Miyuki Miki Yoshimasa Fujita Masao Tanaka Toshihiro Fukushima Toshiro Okazaki Takanori Ueda

Standardized treatments for indolent B cell lymphoma primarily consisting of follicular lymphoma (FL) and for mantle cell lymphoma (MCL) have yet to be established. Here the Hokuriku Hematology Oncology Study Group conducted a multicenter prospective study to investigate the efficacy and safety of a combination regimen of rituximab, cladribine, mitoxantrone, and dexamethasone (R-CMD) in indolen...

Journal: :Cancer 2003
Marco Montillo Alessandra Tedeschi Susan O'Brien Francesco Di Raimondo Susan Lerner Alessandra Ferrajoli Enrica Morra Michael J Keating

BACKGROUND One of the mechanisms of action of cladribine is the inhibition of DNA repair of damage caused by radiation, alkylating agents, or other drugs. To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL). METHODS Twenty-nine pat...

2017
Lilian Aly Bernhard Hemmer Thomas Korn

BACKGROUND Immunosuppressive drugs have been used in the treatment of multiple sclerosis (MS) for a long time. Today, orally available second generation immunosuppressive agents have been approved or are filed for licensing as MS therapeutics. Due to semi-selective targeting of cellular processes, these second-generation immunosuppressive compounds might rather be immunomodulatory. For example,...

2014
Prahlad Ho Carole Smith

Erdheim-Chester disease (ECD) is a rare multisystem non-Langerhans histiocytosis. CNS involvement is a major complication, which is often rapidly progressive and confers a poor prognosis. However, treatment of CNS ECD is difficult due to poor CNS penetrance by the most effective chemotherapeutic drugs commonly used in this disorder (e.g., interferon and cladribine). We describe a case of a 60-y...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید